malignant peripheral nerve sheath tumor
GPTKB entity
Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:letrozole
|
| gptkbp:affects |
nerves
|
| gptkbp:age |
adults
|
| gptkbp:associated_with |
gptkb:neurofibromatosis_type_1
gptkb:neurofibromatosis_type_2 gptkb:motorcycle gptkb:municipality patient outcomes supportive care oncogenes tumor suppressor genes multidisciplinary approach tumor grading treatment resistance metastatic disease malignant transformation surgical margins recurrence risk plexiform neurofibroma tumor staging |
| gptkbp:clinical_trial |
ongoing
completed phase 1 phase 2 phase 3 |
| gptkbp:gender |
both sexes
|
| https://www.w3.org/2000/01/rdf-schema#label |
malignant peripheral nerve sheath tumor
|
| gptkbp:location |
peripheral nerves
|
| gptkbp:occurs_in |
rare
|
| gptkbp:research_areas |
gptkb:physicist
oncology pathology |
| gptkbp:risk_factor |
environmental factors
family history genetic mutations previous radiation exposure |
| gptkbp:social_responsibility |
gptkb:MRI
CT scan variable imaging studies biopsy PET scan |
| gptkbp:symptoms |
pain
swelling weakness numbness tingling |
| gptkbp:treatment |
gptkb:hospital
gptkb:vaccine palliative care quality of life survival rate radiation therapy chemotherapy targeted therapy pain management recurrence metastasis clinical management adjuvant therapy neoadjuvant therapy |
| gptkbp:type |
gptkb:healthcare_organization
|